06.17.2026

Bayer Completes Acquisition of Perfuse Therapeutics, Gains Full Rights to PER-001

Key Takeaways Bayer has completed its acquisition of Perfuse Therapeutics and will fully integrate the company into its operations The deal gives Bayer full rights to PER-001, a phase 2 intravitreal implant being developed for glaucoma and diabetic retinopathy Bayer paid $300 million upfront, with the transaction carrying a potential total value of up to $2.45 billion through milestone payments Bayer has completed its acquisition of Perfuse Therapeutics, bringing the ophthalmology-focused biotechnology company fully into Bayer’s organization and securing full rights to PER-001, an investigational intravitreal implant currently in phase 2 clinical development for glaucoma and diabetic retinopathy (DR). In May, Bayer has entered into an agreement to acquire Perfuse.